These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 32639887)

  • 41. Cardiovascular Safety of Incretin-Based Therapies in Type 2 Diabetes: Systematic Review of Integrated Analyses and Randomized Controlled Trials.
    Mannucci E; Monami M
    Adv Ther; 2017 Jan; 34(1):1-40. PubMed ID: 27844335
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Impact of glucagon-like peptide 1 receptor agonists and sodium-glucose transport protein 2 inhibitors on blood pressure and lipid profile.
    Muzurović E; Mikhailidis DP
    Expert Opin Pharmacother; 2020 Dec; 21(17):2125-2135. PubMed ID: 32697112
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Meta-analysis of dipeptidyl peptidase-4 inhibitors use and cardiovascular risk in patients with type 2 diabetes mellitus.
    Kaneko M; Narukawa M
    Diabetes Res Clin Pract; 2016 Jun; 116():171-82. PubMed ID: 27321333
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effects of Dipeptidyl Peptidase 4 Inhibitors and Sodium-Glucose Linked coTransporter-2 Inhibitors on cardiovascular events in patients with type 2 diabetes mellitus: A meta-analysis.
    Savarese G; D'Amore C; Federici M; De Martino F; Dellegrottaglie S; Marciano C; Ferrazzano F; Losco T; Lund LH; Trimarco B; Rosano GM; Perrone-Filardi P
    Int J Cardiol; 2016 Oct; 220():595-601. PubMed ID: 27390996
    [TBL] [Abstract][Full Text] [Related]  

  • 45. First-Line Therapy for Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists : A Cost-Effectiveness Study.
    Choi JG; Winn AN; Skandari MR; Franco MI; Staab EM; Alexander J; Wan W; Zhu M; Huang ES; Philipson L; Laiteerapong N
    Ann Intern Med; 2022 Oct; 175(10):1392-1400. PubMed ID: 36191315
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparisons of diabetic retinopathy events associated with glucose-lowering drugs in patients with type 2 diabetes mellitus: A network meta-analysis.
    Tang H; Li G; Zhao Y; Wang F; Gower EW; Shi L; Wang T
    Diabetes Obes Metab; 2018 May; 20(5):1262-1279. PubMed ID: 29369494
    [TBL] [Abstract][Full Text] [Related]  

  • 47. GLP-1 receptor agonist versus DPP-4 inhibitor and kidney and cardiovascular outcomes in clinical practice in type-2 diabetes.
    Xu Y; Fu EL; Clase CM; Mazhar F; Jardine MJ; Carrero JJ
    Kidney Int; 2022 Feb; 101(2):360-368. PubMed ID: 34826514
    [TBL] [Abstract][Full Text] [Related]  

  • 48. How Do SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors and GLP-1 (Glucagon-Like Peptide-1) Receptor Agonists Reduce Cardiovascular Outcomes?: Completed and Ongoing Mechanistic Trials.
    Lee MMY; Petrie MC; McMurray JJV; Sattar N
    Arterioscler Thromb Vasc Biol; 2020 Mar; 40(3):506-522. PubMed ID: 31996025
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Absolute treatment effects for the primary outcome and all-cause mortality in the cardiovascular outcome trials of new antidiabetic drugs: a meta-analysis of digitalized individual patient data.
    Kuss O; Akbulut C; Schlesinger S; Georgiev A; Kelm M; Roden M; Wolff G
    Acta Diabetol; 2022 Oct; 59(10):1349-1359. PubMed ID: 35879478
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cardiovascular safety outcomes of new antidiabetic therapies.
    LeBras MH; Barry AR; Koshman SL
    Am J Health Syst Pharm; 2017 Jul; 74(13):970-976. PubMed ID: 28483748
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Calibrating a network meta-analysis of diabetes trials of sodium glucose cotransporter 2 inhibitors, glucagon-like peptide-1 receptor analogues and dipeptidyl peptidase-4 inhibitors to a representative routine population: a systematic review protocol.
    Butterly E; Wei L; Adler AI; Almazam SAM; Alsallumi K; Blackbourn LAK; Dias S; Hanlon P; Hughes K; Lewsey J; Lindsay R; McGurnaghan S; Petrie J; Phillippo D; Sattar N; Tomlinson LA; Welton N; Wild S; McAllister D
    BMJ Open; 2022 Oct; 12(10):e066491. PubMed ID: 36302574
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The cardiovascular benefits of GLP1-RAs are related to their positive effect on glycemic control: A meta-regression analysis.
    Ghosal S; Sinha B
    Diabetes Res Clin Pract; 2022 Apr; 186():109824. PubMed ID: 35271879
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Revisiting 'intensive' blood glucose control: A causal directed acyclic graph-guided systematic review of randomized controlled trials.
    Huang CJ; Wang WT; Sung SH; Chen CH; Lip GYH; Cheng HM; Chiang CE
    Diabetes Obes Metab; 2022 Dec; 24(12):2341-2352. PubMed ID: 35848464
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [New oral antidiabetic drugs].
    Müller-Wieland D; Schütt K; Brandts J; Marx N
    Herz; 2020 Aug; 45(5):493-503. PubMed ID: 32601754
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prescribing in Type 2 Diabetes Patients With and Without Cardiovascular Disease History: A Descriptive Analysis in the UK CPRD.
    Farmer RE; Beard I; Raza SI; Gollop ND; Patel N; Tebboth A; McGovern AP; Kanumilli N; Ternouth A
    Clin Ther; 2021 Feb; 43(2):320-335. PubMed ID: 33581878
    [TBL] [Abstract][Full Text] [Related]  

  • 56. SGLT-2 inhibitors reduce the risk of cerebrovascular/cardiovascular outcomes and mortality: A systematic review and meta-analysis of retrospective cohort studies.
    Mascolo A; Scavone C; Scisciola L; Chiodini P; Capuano A; Paolisso G
    Pharmacol Res; 2021 Oct; 172():105836. PubMed ID: 34418562
    [TBL] [Abstract][Full Text] [Related]  

  • 57. New Therapeutic Strategies for Type 2 Diabetes
    Yehya A; Sadhu AR
    Methodist Debakey Cardiovasc J; 2018; 14(4):281-288. PubMed ID: 30788014
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Myocardial infarction in type 2 diabetes using sodium-glucose co-transporter-2 inhibitors, dipeptidyl peptidase-4 inhibitors or glucagon-like peptide-1 receptor agonists: proportional hazards analysis by deep neural network based machine learning.
    Yamada T; Iwasaki K; Maedera S; Ito K; Takeshima T; Noma H; Shojima N
    Curr Med Res Opin; 2020 Mar; 36(3):403-409. PubMed ID: 31855074
    [No Abstract]   [Full Text] [Related]  

  • 59. Effects of glucose-lowering on outcome incidence in diabetes mellitus and the modulating role of blood pressure and other clinical variables: overview, meta-analysis of randomized trials.
    Thomopoulos C; Bazoukis G; Ilias I; Tsioufis C; Makris T
    J Hypertens; 2019 Oct; 37(10):1939-1949. PubMed ID: 31157748
    [TBL] [Abstract][Full Text] [Related]  

  • 60. GLP-1 receptor agonists and SGLT2 inhibitors for older people with type 2 diabetes: A systematic review and meta-analysis.
    Karagiannis T; Tsapas A; Athanasiadou E; Avgerinos I; Liakos A; Matthews DR; Bekiari E
    Diabetes Res Clin Pract; 2021 Apr; 174():108737. PubMed ID: 33705820
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.